This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Yuan Y, Iloeje UH, Hay J, Saab S.Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. Journal of Managed Care Pharmacy 14: 21-33, No. 1, Jan-Feb 2008
Rights and permissions
About this article
Cite this article
Entecavir “economically attractive” in US for chronic HBV. Pharmacoecon. Outcomes News 549, 1 (2008). https://doi.org/10.2165/00151234-200805490-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805490-00001